BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ — SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ — SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD

SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology

BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ — SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS’ AI-powered analytics with MD Anderson’s clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.

As part of the collaboration, MD Anderson and SOPHiA GENETICS are launching a series of research and development programs and co-developing an advanced next-generation sequencing oncology test. Built on the advanced AI algorithms of the SOPHiA DDM™ Platform, the new co-developed test aims to translate complex multimodal data into actionable insights with greater speed and scale. MD Anderson researchers will tap SOPHiA GENETICS’ AI technologies to create bioinformatics pipelines that enable clinicians to rapidly interpret complex RNA-sequencing data to guide diagnosis and treatment for patients with cancer.

Donna Hansel, M.D., Ph.D., Division Head of Pathology and Laboratory Medicine at MD Anderson, said: “Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information. This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

In addition, MD Anderson and SOPHiA GENETICS will jointly launch a series of research and development programs to explore new ways to characterize tumor evolution in real time, to strengthen the reliability and reproducibility of complex genomic testing, and to enhance the ability to identify optimal clinical trials or research avenues for individual patients. This multi-layered program is designed to fuel next-generation scientific discovery, empowering clinicians and researchers with tools to better understand the dynamic nature of cancer. The collaborative work at MD Anderson will be led by Shashikant Kulkarni, Ph.D., deputy division head for Molecular Pathology, and J. Bryan, M.D., assistant professor, both in the Division of Pathology and Laboratory Medicine.

Philippe Menu, M.D., Ph.D., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS, said: “This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research. With SOPHiA DDM™ as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.

About SOPHiA GENETICS
SOPHiA GENETICS (NASDAQ: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn

About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-and-md-anderson-announce-strategic-collaboration-to-accelerate-ai-driven-precision-oncology-302654306.html

SOURCE SOPHiA GENETICS

Market Opportunity
SophiaVerse Logo
SophiaVerse Price(SOPHIA)
$0.001198
$0.001198$0.001198
+1.52%
USD
SophiaVerse (SOPHIA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Will Huge $8.3B Bitcoin Options Expiry Trigger Another Dump?

Will Huge $8.3B Bitcoin Options Expiry Trigger Another Dump?

The post Will Huge $8.3B Bitcoin Options Expiry Trigger Another Dump? appeared on BitcoinEthereumNews.com. Home » Crypto News The end of another week is here again
Share
BitcoinEthereumNews2026/01/30 14:01
Why Staffing Agencies Need Hot Desk Booking Software to Scale Smarter

Why Staffing Agencies Need Hot Desk Booking Software to Scale Smarter

Your headcount doubled this year. Congratulations – you’re killing it.  But now you’re staring at a lease renewal and wondering: do you really need 40 desks when
Share
Fintechzoom2026/01/30 14:26
Urgent: Coinbase CEO Pushes for Crucial Crypto Market Structure Bill

Urgent: Coinbase CEO Pushes for Crucial Crypto Market Structure Bill

BitcoinWorld Urgent: Coinbase CEO Pushes for Crucial Crypto Market Structure Bill The cryptocurrency world is buzzing with significant developments as Coinbase CEO Brian Armstrong recently took to Washington, D.C., advocating passionately for a clearer regulatory path. His mission? To champion the passage of a vital crypto market structure bill, specifically the Digital Asset Market Clarity (CLARITY) Act. This legislative push is not just about policy; it’s about safeguarding investor rights and fostering innovation in the digital asset space. Why a Clear Crypto Market Structure Bill is Essential Brian Armstrong’s visit underscores a growing sentiment within the crypto industry: the urgent need for regulatory clarity. Without clear guidelines, the market operates in a gray area, leaving both innovators and investors vulnerable. The proposed crypto market structure bill aims to bring much-needed definition to this dynamic sector. Armstrong explicitly stated on X that this legislation is crucial to prevent a recurrence of actions that infringe on investor rights, citing past issues with former U.S. Securities and Exchange Commission (SEC) Chair Gary Gensler. This proactive approach seeks to establish a stable and predictable environment for digital assets. Understanding the CLARITY Act: A Blueprint for Digital Assets The Digital Asset Market Clarity (CLARITY) Act is designed to establish a robust regulatory framework for the cryptocurrency industry. It seeks to delineate the responsibilities of key regulatory bodies, primarily the SEC and the Commodity Futures Trading Commission (CFTC). Here are some key provisions: Clear Jurisdiction: The bill aims to specify which digital assets fall under the purview of the SEC as securities and which are considered commodities under the CFTC. Investor Protection: By defining these roles, the act intends to provide clearer rules for market participants, thereby enhancing investor protection. Exemption Conditions: A significant aspect of the bill would exempt certain cryptocurrencies from the stringent registration requirements of the Securities Act of 1933, provided they meet specific criteria. This could reduce regulatory burdens for legitimate projects. This comprehensive approach promises to bring structure to a rapidly evolving market. The Urgency Behind the Crypto Market Structure Bill The call for a dedicated crypto market structure bill is not new, but Armstrong’s direct engagement highlights the increasing pressure for legislative action. The lack of a clear framework has led to regulatory uncertainty, stifling innovation and sometimes leading to enforcement actions that many in the industry view as arbitrary. Passing this legislation would: Foster Innovation: Provide a clear roadmap for developers and entrepreneurs, encouraging new projects and technologies. Boost Investor Confidence: Offer greater certainty and protection for individuals investing in digital assets. Prevent Future Conflicts: Reduce the likelihood of disputes between regulatory bodies and crypto firms, creating a more harmonious ecosystem. The industry believes that a well-defined regulatory landscape is essential for the long-term health and growth of the digital economy. What a Passed Crypto Market Structure Bill Could Mean for You If the CLARITY Act or a similar crypto market structure bill passes, its impact could be profound for everyone involved in the crypto space. For investors, it could mean a more secure and transparent market. For businesses, it offers a predictable environment to build and scale. Conversely, continued regulatory ambiguity could: Stifle Growth: Drive innovation overseas and deter new entrants. Increase Risks: Leave investors exposed to unregulated practices. Create Uncertainty: Lead to ongoing legal battles and market instability. The stakes are incredibly high, making the advocacy efforts of leaders like Brian Armstrong all the more critical. The push for a clear crypto market structure bill is a pivotal moment for the digital asset industry. Coinbase CEO Brian Armstrong’s efforts in Washington, D.C., reflect a widespread desire for regulatory clarity that protects investors, fosters innovation, and ensures the long-term viability of cryptocurrencies. The CLARITY Act offers a potential blueprint for this future, aiming to define jurisdictional boundaries and streamline regulatory requirements. Its passage could unlock significant growth and stability, cementing the U.S. as a leader in the global digital economy. Frequently Asked Questions (FAQs) What is the Digital Asset Market Clarity (CLARITY) Act? The CLARITY Act is a proposed crypto market structure bill aimed at establishing a clear regulatory framework for digital assets in the U.S. It seeks to define the roles of the SEC and CFTC and exempt certain cryptocurrencies from securities registration requirements under specific conditions. Why is Coinbase CEO Brian Armstrong advocating for this bill? Brian Armstrong is advocating for the CLARITY Act to bring regulatory certainty to the crypto industry, protect investor rights from unclear enforcement actions, and foster innovation within the digital asset space. He believes it’s crucial for the industry’s sustainable growth. How would this bill impact crypto investors? For crypto investors, the passage of this crypto market structure bill would mean greater clarity on which assets are regulated by whom, potentially leading to enhanced consumer protections, reduced market uncertainty, and a more stable investment environment. What are the primary roles of the SEC and CFTC concerning this bill? The bill aims to delineate the responsibilities of the SEC (Securities and Exchange Commission) and the CFTC (Commodity Futures Trading Commission) regarding digital assets. It seeks to clarify which assets fall under securities regulation and which are considered commodities, reducing jurisdictional ambiguity. What could happen if a crypto market structure bill like CLARITY Act does not pass? If a clear crypto market structure bill does not pass, the industry may continue to face regulatory uncertainty, potentially leading to stifled innovation, increased legal challenges for crypto companies, and a less secure environment for investors due to inconsistent enforcement and unclear rules. Did you find this article insightful? Share it with your network to help spread awareness about the crucial discussions shaping the future of digital assets! To learn more about the latest crypto market trends, explore our article on key developments shaping crypto regulation and institutional adoption. This post Urgent: Coinbase CEO Pushes for Crucial Crypto Market Structure Bill first appeared on BitcoinWorld.
Share
Coinstats2025/09/18 20:35